Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind randomized study of filgotinib vs adalimumab and placebo in biologic-naive active psoriatic arthritis
jRCT2080225107Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of filgotinib in psoriatic arthritis (PsA) (4 arms), sponsored by Gilead Sciences. Started Mar 2020; status: completed.
02
Drugs
filgotinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on jRCT2080225107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225107.